News Detail
JERSEY CITY, 11 MARCH 2025: Celltrion announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab) for the treatment ......
View Details
Source : PRNewswire
Celltrion
U.S. Food and Drug Administration (FDA)
approved OMLYCLO®
omalizumab-igec
biosimilar
XOLAIR®
omalizumab
persistent asthma
chronic rhinosinusitis with nasal polyps (CRSwNP)
Immunoglobulin E (IgE)-mediated food allergy
chronic spontaneous urticaria (CSU)
Related News
- Health department orders to recall batch of ‘spurious Telma AM 40’ used for hypertension (12-03-2025)
- Zydus Life inks pact to acquire majority stake in Amplitude Surgical (12-03-2025)
- Steps taken to prioritize Research on Fungal Infections (12-03-2025)
- 1500 Pregabalin capsules seized from four places, four accused arrested (12-03-2025)
- India ranked 11th in global pharma exports in 2023: Anupriya Patel (12-03-2025)
- ED arrests 2 from Lucknow for shipping 'banned' drugs to US clients (12-03-2025)
- Scientists claim major breakthrough in developing vaccine for stroke and heart attack (12-03-2025)
- Extortion Racket at Ayurvedic Center Busted: Three Arrested (11-03-2025)
- Assam: One held in Cachar with 98,000 Yaba tablets worth Rs 30 crore (11-03-2025)
- CCRH and Adamas University Sign MoU to Advance Homoeopathy Research (11-03-2025)